The present investigation is aimed to formulate & characterize the immediate release tablet of Efavirenz by using Soluplus as a polymer. The proposed formulation of the immediate release tablet of Efavirenz are prepared by using solid dispersion by hot melt technique to improve solubility and dissolution rate of poorly water soluble Efavirenz . The drug to polymer ratio in optimized batch (TABSD13) was 1:3. The obtained batch was characterized for its percent drug contenet, thermal analysis (DSC), crystallinity (PXRD), FTIR and in vitro drug release. There were no compatibility issues and the crystallinity of drug was found to be reduced in prepared tablet which were confirmed by DSC and PXRD studies. The average dissolution rate of six Efavirenz tablet & marketed formulation in 0.5 % SLS in distilled water in 45 min were 72.77 % & 69.37 % respectively while in 120 min they were about 90.08 % & 88.24 % respectively & the standard deviations were also within the limits. It shows that the dissolution profiles of hot melt Efavirenz tablet & Marketed formulation were comparable in 0.5 % SLS in distilled water. This may be because of the SLS which act as good surfactant. Further investigations are required to reduce the amount of polymer in tablet that can provide maximum drug loading and acceptable dosage form.
Introduction
Almost 60% of drug molecule available in market possesses either solubility or permeability related pharmacokinetic problems. The most important and common problem associated with the oral dosage form is low aqueous solubility of drug not only in dissolution media but also in gastrointestinal fluid. It is hence most important for budding formulation scientist to understand BCS classification, technology to improve bioavailability & analytical methods to study the bioavailability. In this project we have carried out reference work on solubility, BCS classification, technique to improve solubility, co-relation between solubility & bioavailability. By taking one example i.e. Efavirenz we have studied hot melt technique & compared the results with the marketed formulation. Melt extrusion is essentially the same as the fusion method except that the extruder induces intense mixing of the components. When compared to melting in a vessel, the product stability and dissolution are similar, but melt extrusion offers the potential to shape the heated *Corresponding Author:
vikramsinh.deshmukh@yahoo.com drug-matrix mixture into implants, ophthalmic inserts, or oral dosage forms. Just like in the traditional fusion process, miscibility of drug and matrix can be a problem. Solubility parameters are investigated to predict the solid-state miscibility and to select matrices suitable for melt extrusion. High shear forces resulting in high local temperatures in the extruder be a problem for heat sensitive materials. However, compared to the traditional fusion method, this technique offers the possibility of continuous production, which makes it suitable for large-scale production. Furthermore, the product is easier to handle because at the outlet of the extruder the shape can be adapted to the next processing step without grinding. As compare to other techniques of preparation of solid dispersion, hot melt extrusion process offers advantage of being Continuous, Reproducible, Fairly high throughput, Dust reduction, On-line monitoring of process. It is a striking example of a technology transfer establishing a new technology life cycle curve .The melt extrusion process is capable of handling active agents of different particle sizes as well as amorphous solids or other polymorphic forms leading to the same product. The use of melts in order to obtain solid molecular dispersions, e.g. glass or solid solutions, is well known to the expert and the essential advantage of a melt process in this domain is its solvent-free formation of such dispersions .Since with solvent processes there are various problems relating to their use (environmental pollution, explosion-proofing and residual organic solvent) and measures to counteract these problems are desirable. Starting from the plastic industry, today melt extrusion has found its place in the array of pharmaceutical manufacturing operations. Melt extrusion processes are currently applied in the pharmaceutical field for the manufacture of a variety of dosage forms and formulations such as granules, pellets, tablets, suppositories, implants, stents, transdermal systems and ophthalmic inserts. As a specific area melt extrusion process used to the manufacture of solid dispersions, in particular, solid molecular dispersions. Melt extrusion is considered to be an efficient technology in this field with particular advantages over solvent processes like coprecipitation. Potential drawbacks like the influence of heat stress and shear forces on the drug active have been overcome in a number of examples with drugs of different chemical structure. Improved bioavailability was achieved again demonstrating the value of the technology as a drug delivery tool. The various types of extruders have a common feature of forcing the extrudate from a wider cross-section through the restriction of the die. The most important application of extrusion in the pharmaceutical industry is in the preparation of granules or pellets of uniform size, shape, and density, containing one or more Drugs. Melt extrusion for the manufacture of pellets had revealed the potential for controlled release of polymer embedded drugs. The use of melts in order to obtain solid molecular dispersions, e.g. glass or solid solutions, is well known to the expert and the essential advantage of a melt process in this domain is its Solvent-free formation of such dispersions which can be formulated by hot melt extrusion technology. This process can be used for formulation of pharmaceutical implants, oral dosage forms, bioadhesive ophthalmic inserts, topical films, and effervescent tablets etc. Melt extrusion technology today represents an efficient pathway for the manufacture of drug delivery systems. Resulting products are mainly found amongst semi-solid and solid preparations. The potential of the technology is reflected in the wide scope of different dosage forms covering oral, parenteral and topical applications. In addition, the physical state of the drug in the melt extruded formulations reaches from simple crystalline embeddings, mainly in the field of sustained release applications, to amorphous or molecularly dissolved stages. Compared to solvent processes aiming at solid molecular dispersions melt extrusion offers a promising alternative. The possible use of a broad selection of excipients from high molecular weight polymers to low molecular weight additives like sugar alcohols, waxes or surfactants opens a field of numerous combinations for formulation research. Present investigation is attempt for improvement in solubility and dissolution rate of poorly water soluble Efavirenz by solid dispersions with the use of Soluplus as polymer with aim to improve the bioavailability, the pharmacokinetic properties and the patient compliance.
Materials and Methods
Commercial 
Pharmaceutical characterization Drug Content
The percent drug content in the solid dispersion were estimated by dissolving quantities equivalent to 10 mg of Efavirenz in 10 ml methanol and filtered through 0.45μm membrane filter, appropriately diluted with distilled water and the UV absorbance were recorded at 248 nm. The percent drug content was recorded by slope method.
Saturation Solubility
The saturation solubility of physical mixture & solid dispersion prepared by hot melt method were determined by equilibrating excess powder in distilled water as well as in 1% SLS in distilled water. The suspensions were stirred for 48 hours on an incubator shaker bath (C24KC, Refrigerated incubator shaker) at 120 rpm at the temperature of 37±0.50C. The solutions were then centrifuged (Eppendorf, centrifuge 5810R, Hamburg, Germany) at 7000 rpm for 10 mins supernatant was filtered through 0.45μm membrane filter, appropriately diluted and analyzed for Efavirenz spectrophotometrically at 248 nm.
Infrared Spectroscopy
All the physical mixtures and solid dispersions prepared by hot melt method were analyzed by FTIR (Jasco FT/IR-4100, Japan). The mixtures were mixed with KBr in mortar and pestle. The resulting mixture was then analyzed in FTIR and the range from 4000 to 400 nm.
Crystallographic Investigation Differential Scanning Calorimetry (DSC)
The DSC measurements were performed using Differential Scanning Calorimeter (DSC Q100, TA instruments). The samples of about 5-10 mg were hermetically sealed in aluminum pans and heated at a constant rate of 10 °C/min over a temperature range of25-200 °C. An inert atmosphere was maintained by purging with nitrogen gas at a flow rate of 100 ml/min. An empty aluminum pan was used as reference.
[[
Powder x-ray diffraction (XRPD)
The XRPD patterns were recorded on an X-ray diffractometer (Miniflex II, Rigaku). The samples were irradiated with monochromatized CuKα radiation (1.542 Å) and analyzed between 2 and 60° 2θ. The voltage and current used were 30 kV and 30 mA, respectively. The range and the chart speed were 1×104 CPS and 10 mm/°2θ, respectively.
Granules properties

Flow properties
The flow properties of granules were carried out in terms of angle of repose (θ), Hausner's ratio and Carr's Index. A weighed quantity of the sample was poured into a graduated cylinder and volume was calculated. Then mechanically tap the cylinder containing the sample by raising the cylinder & allowing it to drop under its own weight using the suitable mechanical tapped density tester (Electro lab ETD-1020, Mumbai India) that provide a fixed drop of 14 2 mm at a nominal rate of 300 drops per min . Unless otherwise specified, tap the cylinder 500 times initially & measure the tapped volume, V, to a nearest graduated unit. Repeat the tapping additional 750 times &measure the tapped volume V, to a nearest graduated unit. If the difference between the two tapped volume is less than 2%, V, is the final tapped volume. Repeat in increments of 1250 taps, as needed, until the difference between two successive measurements is less than 2 %.calculate the tapped density by using the formula (3). The packing properties of powders were determined using following equations. Angle of repose For determination of angle of repose (θ), the powder were poured through the wall of a funnel, which was fixed at a position such that its lower tip was at a height of exactly 2.0 cm above hard surface. The powders were poured till the tip of the pile surface touched the lower tip of the funnel & the radius of the base of pile was measured. 
Evaluation of Tablets
Prepared tablets were evaluated for the following parameters:
Thickness
The thickness of the tablets was determined using Vernier caliper. 5 tablets from batch were used and average values were calculated.
Hardness
The hardness of 6 tablets was determined using Monsanto hardness tester & average value of 6 tablets was calculated.
Weight Variation 20 tablets were selected randomly and weighed individually. The total weight of 20 tablets was calculated and average weight was determined. Not more than 2 of the individual weights deviate from the average weight by more than 10%.
Friability
The friability of 10 tablets was measured using a Roche Friabilator (EF-2, Electro lab, India). Tablets were rotated at 25 rpm for 4 minutes. The tablets were then re-weighed after dedusting and the % friability was calculated using formula no. 9 .The maximum weight loss should not be more than 1%. 
Assay
The assay of the tablet was determined by the procedure given in the IP as follows.
Test Solution
Weigh & powder 20 tablets. Weigh accurately a quantity of tablets powder containing about 100 mg of Efavirenz & shake with sufficient methanol to obtain a mixture containing 6 mg of Efavirenz per ml. Sonicate the solution using bath sonicator for 20 min to ensure complete solubilization of drug in solution. Filter the solution through a membrane filter disc with an average pore diameter of 1.0 μm. Rejecting first few ml of filtrate and dilute 10.0 ml of the filtrate to 50.0ml with methanol. The absorbance of the above solution is taken on UV spectrophotometer (UV1800, SHIMADZU, Japan) at 248 nm.
Reference solution A 0.12 % w/v solution of Efavirenz in methanol. The % of the Efavirenz in tablet is calculated from the slope of calibration curve of Efavirenz in methanol.
IP Limit
The Efavirenz tablet should contains not less than 90% and not more than 110 % of the stated amount of C14H9Cl F3NO2.
Measurement of Disintegration time:
The disintegration test was carried out using an Electrolab disintegration test apparatus (model ED2L, Electro lab.) The volume of disintegration medium (distilled water) used was 1000 ml; 1 tablet in each of 6 tubes of basket was carefully placed and if prescribed add a disk. Operate the apparatus using water or the specified medium as immersion fluid, maintained at 37o 2oC. At the end of the time specified basket was lifted from the fluid & observes the tablets. All of the tablets have disintegrate completely, if one or two tablets failed to disintegrate completely, then repeat the test on additional 12 tablets. The requirement is met if not more than 16 of total 18 tablets are disintegrated Dissolution studies Dissolution study was conducted using the USP type II apparatus (USP type II TDL-08L Electro lab) at 50 rpm in 900 ml of 1% sodium lauryl sulphate in distilled water and at 37±0.50 c. The drug was analyzed spectrophotometrically at 248 nm The tablets containing 100mg of Efavirenz were placed in dissolution medium and apparatus was run maintaining above stated test conditions. 5 ml aliquot was withdrawn at time points of 5 min., 10 min., 15 min., 30 min., 45 min., 60 min., 90 min., and 120 min. and was replenished with fresh dissolution medium. The samples were estimated for Efavirenz content spectrophotometrically at 248nm. Percentage drug release was calculated Dissolution studies in Discriminating Medias 1) 0.5 % SLS in distilled water 2) 0.1N HCl
Calculation of Similarity Factor
The similarity factor was calculated by following formula. This approach uses a similarity factor (f2) to compare dissolution profiles. The similarity factor f2 is a logarithmic reciprocal square root transformation of the sum of squared error and is measurement of the similarity in the percent dissolution between the two curves. f2 = 50* log {[1+1/n Rt −Tt 2nt=1] 0.5* 100}
Where n is the number of time points, Rt is the dissolution value of the reference batch at time t, and Tt is the dissolution value of the test batch at time t.
Stability Studies
Stability studies of tablets were performed as per ICH guidelines. The tablets from the optimized batch (TABSD13) were stability tested by using following protocol
Results and Discussion
Characterization of Efavirenz Melting point of Efavirenz
The melting point of Efavirenz was found to be 137.440C. This is within the accepted range as specified in Merck Index. The FTIR spectra of the pure Efavirenz were recorded in the wavelength range of 4000 to 400 nm. It shows characteristic peak at 3363 cm-1 , 3052 cm-1 , 2944 cm-1, 2300 cm-1, 1691 cm-1,1602 cm-1, 1217 cm-1 & 1326 cm-1 attributed to N-H stretching vibrations, aromatic C-H stretching vibration, aliphatic C-H stretching vibration, C≡C cm-1 stretching vibration, C=O stretching vibration , C=C stretching vibration, C-F stretching vibration , C-O-C stretching vibration respectively. The spectrum matches reference as given in Flory series.
FTIR spectroscopy Structure of Efavirenz
Calibration curves of Efavirenz
Calibration curve of Efavirenz in 1 % SLS in water, 0.1NHCl & in distilled water was carried out. The resulting graphs &equation are represented in the following figure No. 3.
Saturation solubility of drug
The saturation solubility of Efavirenz in distilled water, in 0.1 N HCl & in 1 % SLS in distilled water at room temperature was found to be 6.5μg/ml, 0.4036μg/ml & 17.5 μg/ml respectively.
Intrinsic dissolution rate (IDR)
The intrinsic dissolution rate testing of the pure Efavirenz & the granules of Efavirenz along with Soluplus & Cremophor EL prepared by the hot melt technique was carried out using type II apparatus at 50 rpm in 1% SLS dissolution medium. The IDR of the pure drug in the dissolution medium was found to be 0.058 ± 0.0068 mg /min/cm2 while the IDR of the Efavirenz granules prepared with Soluplus & Cremophor EL was found 0.1166 ± 0.007 mg /min/cm2. As the intrinsic dissolution rate of drug was found to be 0.058 mg /min/cm2 which suggests dissolution rate-limited absorption problems for this drug because drugs having the dissolution rate less than 0.1 mg /min/cm2 have the dissolution rate limited absorption problems36. There was about two fold increase in the IDR of the Efavirenz granules as compare to the pure Efavirenz. This was attributed to increased wetting of the drug particles by the polymer as well as solublization of drug in hydrophilic polymer and formation of polymer coat around the drug particles. Hence we can conclude that the increase in IDR indicates that hot melt technique is capable of increasing the dissolution rate of Efavirenz. Comparison of dissolution profile of hot melt Efavirenz tablet with marketed formulation showed comparable dissolution profile. Similarity factor for optimized batch (TABSD13) with marketed formulation was found to be 70.94 which highly significant. Comparison of dissolution profile of hot melt Efavirenz tablet with marketed formulation showed higher dissolution rate in 0.1N HCl. There is a 10-15 % difference in the dissolution profile. This signifies that hot melt products are more soluble in acidic condition as compared to marketed formulation. Thus, in conclusion 'hot melt 'technique can be used to manufacture an Efavirenz tablets. Based on the dissolution studies in acidic condition these tablets can be better bioavailable than current formulation in market .Further studies are required to correlate the hypothesis. 
